Literature DB >> 30898897

External validation and recalibration of the Brock model to predict probability of cancer in pulmonary nodules using NLST data.

Audrey Winter1, Denise R Aberle2, William Hsu2.   

Abstract

INTRODUCTION: We performed an external validation of the Brock model using the National Lung Screening Trial (NLST) data set, following strict guidelines set forth by the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis statement. We report how external validation results can be interpreted and highlight the role of recalibration and model updating.
MATERIALS AND METHODS: We assessed model discrimination and calibration using the NLST data set. Adhering to the inclusion/exclusion criteria reported by McWilliams et al, we identified 7879 non-calcified nodules discovered at the baseline low-dose CT screen with 2 years of follow-up. We characterised differences between Pan-Canadian Early Detection of Lung Cancer Study and NLST cohorts. We calculated the slope on the prognostic index and the intercept coefficient by fitting the original Brock model to NLST. We also assessed the impact of model recalibration and the addition of new covariates such as body mass index, smoking status, pack-years and asbestos.
RESULTS: While the area under the curve (AUC) of the model was good, 0.905 (95% CI 0.882 to 0.928), a histogram plot showed that the model poorly differentiated between benign and malignant cases. The calibration plot showed that the model overestimated the probability of cancer. In recalibrating the model, the coefficients for emphysema, spiculation and nodule count were updated. The updated model had an improved calibration and achieved an optimism-corrected AUC of 0.912 (95% CI 0.891 to 0.932). Only pack-year history was found to be significant (p<0.01) among the new covariates evaluated.
CONCLUSION: While the Brock model achieved a high AUC when validated on the NLST data set, the model benefited from updating and recalibration. Nevertheless, covariates used in the model appear to be insufficient to adequately discriminate malignant cases. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Brock model; external validation; lung cancer; prediction; recalibration

Mesh:

Year:  2019        PMID: 30898897     DOI: 10.1136/thoraxjnl-2018-212413

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  6 in total

1.  Lung cancer screening: tell me more about post-test risk.

Authors:  Mario Silva; Gianluca Milanese; Ugo Pastorino; Nicola Sverzellati
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

2.  Developing an understanding of artificial intelligence lung nodule risk prediction using insights from the Brock model.

Authors:  Madhurima R Chetan; Nicholas Dowson; Noah Waterfield Price; Sarim Ather; Angus Nicolson; Fergus V Gleeson
Journal:  Eur Radiol       Date:  2022-03-03       Impact factor: 7.034

3.  Optimizing the timing of diagnostic testing after positive findings in lung cancer screening: a proof of concept radiomics study.

Authors:  Zixing Wang; Ning Li; Fuling Zheng; Xin Sui; Wei Han; Fang Xue; Xiaoli Xu; Cuihong Yang; Yaoda Hu; Lei Wang; Wei Song; Jingmei Jiang
Journal:  J Transl Med       Date:  2021-05-04       Impact factor: 5.531

Review 4.  Implications of the updated Lung CT Screening Reporting and Data System (Lung-RADS version 1.1) for lung cancer screening.

Authors:  Spencer C Dyer; Brian J Bartholmai; Chi Wan Koo
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

5.  Comprehensive Analysis of Clinical Logistic and Machine Learning-Based Models for the Evaluation of Pulmonary Nodules.

Authors:  Kai Zhang; Zihan Wei; Yuntao Nie; Haifeng Shen; Xin Wang; Jun Wang; Fan Yang; Kezhong Chen
Journal:  JTO Clin Res Rep       Date:  2022-02-22

6.  Study on the Prediction Method of Long-term Benign and Malignant Pulmonary Lesions Based on LSTM.

Authors:  Xindong Liu; Mengnan Wang; Rukhma Aftab
Journal:  Front Bioeng Biotechnol       Date:  2022-03-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.